Industry Roundup: Nature’s Way Licenses Chromax, Tauriga moves to supplements
This article was originally published in The Tan Sheet
Executive Summary
Nutrition 21, Nature’s Way settle patent case; Tauriga moves from food to supplements; Miami firm banned from weight loss market; national sales for Mary’s Nutritionals; and more news in brief.
You may also be interested in...
Pfizer Licenses Nutrition 21’s Chromax In Patent Claim Settlement
The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.
ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer
While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.